Halozyme Therapeutics, Inc. (NASDAQ:HALO) Forecasted to Earn Q3 2025 Earnings of $1.01 Per Share

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Investment analysts at Zacks Research boosted their Q3 2025 earnings per share (EPS) estimates for Halozyme Therapeutics in a research note issued on Monday, April 22nd. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will earn $1.01 per share for the quarter, up from their previous forecast of $0.98. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.45 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ FY2025 earnings at $3.92 EPS and Q1 2026 earnings at $1.21 EPS.

HALO has been the topic of several other reports. Benchmark reissued a “buy” rating and set a $50.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday, April 16th. TD Cowen started coverage on Halozyme Therapeutics in a research report on Thursday, February 29th. They set an “outperform” rating and a $54.00 price target on the stock. JMP Securities reissued a “market outperform” rating and set a $72.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, February 21st. TheStreet lowered Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research report on Monday, January 22nd. Finally, StockNews.com upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, February 23rd. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $53.29.

Halozyme Therapeutics Stock Up 0.4 %

Shares of Halozyme Therapeutics stock opened at $39.12 on Tuesday. The stock’s fifty day moving average is $39.71 and its 200-day moving average is $37.79. The firm has a market capitalization of $4.97 billion, a PE ratio of 18.54, a price-to-earnings-growth ratio of 0.45 and a beta of 1.25. The company has a quick ratio of 5.50, a current ratio of 6.64 and a debt-to-equity ratio of 17.89. Halozyme Therapeutics has a 12-month low of $29.85 and a 12-month high of $45.00.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The company had revenue of $230.04 million for the quarter, compared to analyst estimates of $235.25 million. Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $38.49, for a total value of $384,900.00. Following the completion of the transaction, the senior vice president now owns 168,176 shares of the company’s stock, valued at approximately $6,473,094.24. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders sold a total of 30,000 shares of company stock valued at $1,196,800 in the last quarter. Corporate insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Advisors Asset Management Inc. raised its holdings in shares of Halozyme Therapeutics by 0.6% in the 3rd quarter. Advisors Asset Management Inc. now owns 45,598 shares of the biopharmaceutical company’s stock worth $1,742,000 after buying an additional 287 shares in the last quarter. First Horizon Advisors Inc. raised its holdings in shares of Halozyme Therapeutics by 24.5% in the 4th quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 293 shares in the last quarter. Fifth Third Bancorp raised its holdings in shares of Halozyme Therapeutics by 2.6% in the 3rd quarter. Fifth Third Bancorp now owns 12,262 shares of the biopharmaceutical company’s stock worth $468,000 after buying an additional 308 shares in the last quarter. Commonwealth Equity Services LLC increased its holdings in Halozyme Therapeutics by 2.2% during the 3rd quarter. Commonwealth Equity Services LLC now owns 16,216 shares of the biopharmaceutical company’s stock valued at $619,000 after purchasing an additional 347 shares in the last quarter. Finally, FCF Advisors LLC increased its holdings in Halozyme Therapeutics by 1.9% during the 1st quarter. FCF Advisors LLC now owns 21,164 shares of the biopharmaceutical company’s stock valued at $861,000 after purchasing an additional 391 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.